Literature DB >> 23727685

Primary pleural of mucosa-associated lymphoid tissue lymphoma.

Atsuko Yamada1, Keiji Sugimoto, Kei Matuno, Miyuki Tutui, Yuriko Yahata, Yutaka Tsukune, Michiaki Koike, Norio Komatsu.   

Abstract

A 68-year-old female presented with shortness of breath. Chest radiography showed pleural effusion in the right side only. She was suspected of having ovarian cancer because CA125 levels were increased in the pleural effusion, and she consulted our hospital. A chest CT scan showed right pleural nodular lesions. Thoracoscopic pleural resection was performed. Histologic examination of a biopsy specimen showed the diffuse infiltration of small∼medium, mature lymphocytes. These lymphocytes were found to be positive for CD20 and CD79a, but negative for CD3 by immunohistochemistry. These results were interpreted as being consistent with a diagnosis of mucosa-associated lymphoid tissue lymphoma (MALT lymphoma). She commenced chemotherapy with R-CHOP, and the pleural effusion disappeared. MALT lymphoma arising in the pleura is very rare, with only 12 published cases, and most cases have been described in Japan. CA125 levels correlated with the stage, tumor bulk, and presence of effusion. This patient exhibited a high level of CA125 that decreased with therapy.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23727685

Source DB:  PubMed          Journal:  Rinsho Ketsueki        ISSN: 0485-1439


  2 in total

1.  Misdiagnosis of primary mucosa-associated lymphoid tissue lymphoma of the pleura: case report and literature review.

Authors:  Yao-Hui Wang; Ling Peng; Jie-Han Jiang; Yun Xiao; Zhi-Ruo Zhu; Zhi-Hui Shi; Wen-Long He; Qing-Wu Qin; Ding Liang; Yi Jiang; Hong Luo; Rui Zhou; Kui Xiao
Journal:  Transl Cancer Res       Date:  2022-09       Impact factor: 0.496

2.  Genetic heterogeneity and mutational signature in Chinese Epstein-Barr virus-positive diffuse large B-cell lymphoma.

Authors:  Fang Liu; Zhe Wang; Xiaoge Zhou; Qing Liu; Gang Chen; Hualiang Xiao; Weihua Yin; Shigeo Nakamura; Huilan Rao
Journal:  PLoS One       Date:  2018-08-14       Impact factor: 3.240

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.